Patents Assigned to Galderma Research & Development
  • Publication number: 20220081519
    Abstract: A new hydrogel made of crosslinked glycosaminoglycans, particularly crosslinked hyaluronic acid, chondroitin or chondroitin sulfate, having reversible linkages using boronic acid or boroxole derivatives leading to new benefits. Glycosaminoglycans that are crosslinked via an alkoxyboronate ester anion formed between a diol portion of a diol-functional moiety grafted to a first glycosaminoglycan and a boronate hemiester grafted to a second glycosaminoglycan.
    Type: Application
    Filed: November 24, 2021
    Publication date: March 17, 2022
    Applicants: Galderma Research & Development, Centre National de la Recherche Scientifique
    Inventors: Rachel AUZELY-VELTY, Tamiris FIGUEIREDO, Laura JING JING, Craig Steven HARRIS, Jean-Guy BOITEAU, Thibaut GERFAUD, Loic TOMAS
  • Patent number: 10995052
    Abstract: Compounds of general formula (I) are described. Also described, is the use of such compounds in pharmaceutical compositions for use in human or veterinary medicine (dermatological, rheumatic, respiratory, cardiovascular and ophthalmologic disorders, in particular), or in cosmetic compositions.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: May 4, 2021
    Assignee: Galderma Research & Development
    Inventor: Thibaud Portal
  • Patent number: 10987307
    Abstract: A self-foaming composition is described that includes ivermectin, for a no-rinse topical application and for application to the skin. The composition can include: at least one intermediate composition B including a gas-generating agent; at least one intermediate composition A including an agent for activating the gas-generating agent; and ivermectin being present in the composition A, in the composition B, or simultaneously in the two compositions A and B. Also described, is a kit or a single container including a plurality of compartments including such a composition.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: April 27, 2021
    Assignee: Galderma Research & Development
    Inventors: Jean-Christophe Buge, Karine Nadau-Fourcade
  • Publication number: 20210096120
    Abstract: The invention relates to a method for determining in vitro release rate of at least one active principle ingredient from at least one semisolid form.
    Type: Application
    Filed: September 11, 2020
    Publication date: April 1, 2021
    Applicant: Galderma Research & Development
    Inventors: Brzokewicz Alain, Hélène Huguet
  • Patent number: 10953094
    Abstract: The present invention is related to a pulse photodynamic therapy (or pulse PDT) treatment of photodamaged skin.
    Type: Grant
    Filed: June 8, 2020
    Date of Patent: March 23, 2021
    Assignee: Galderma Research & Development
    Inventors: Hans Christian Wulf, Gloria Sanclemente
  • Patent number: 10647688
    Abstract: Novel compounds, synthesis methods and use of the same in medicine and in cosmetics are disclosed. Also disclosed, are novel compounds and ligands that modulate RARs.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: May 12, 2020
    Assignee: Galderma Research & Development
    Inventor: Thibaud Portal
  • Publication number: 20200062868
    Abstract: A new hydrogel made of crosslinked glycosaminoglycans, particularly crosslinked hyaluronic acid, chondroitin or chondroitin sulfate, having reversible linkages using boroxole derivatives leading to new benefits. Glycosaminoglycans that are crosslinked via an alkoxyboronate ester anion formed between a backbone diol function of a first glycosaminoglycan and a boronate hemiester grafted to a second glycosaminoglycan.
    Type: Application
    Filed: August 2, 2017
    Publication date: February 27, 2020
    Applicants: Galderma Research & Development, Centre National de la Recherche Scientifique
    Inventors: Rachel AUZELY-VELTY, Tamiris FIGUEIREDO, Laura JING JING, Craig Steven HARRIS, Jean-Guy BOITEAU, Thibaut GERFAUD, Loic TOMAS
  • Publication number: 20200002441
    Abstract: A new hydrogel made of double crosslinked glycosaminoglycans, particularly crosslinked hyaluronic acid, chondroitin or chondroitin sulfate, having reversible linkages using boronic acid or boroxole derivatives leading to new benefits. Double crosslinked glycosaminoglycans, one linkage via two ether bonds with a hydroxyl group of each of two glycosaminoglycans and another linkage via an alkoxyboronate ester anion formed between a boronate hemiester grafted to one of the glycosaminoglycans and a diol function of to the other glycosaminoglycan. The diol function may be a backbone diol function or a diol portion of a diol functional moiety grafted the other glycosaminoglycan.
    Type: Application
    Filed: August 2, 2017
    Publication date: January 2, 2020
    Applicants: Galderma Research & Development, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Rachel AUZELY-VELTY, Tamiris FIGUEIREDO, Laura JING JING, Craig Steven HARRIS, Jean-Guy BOITEAU, Thibaut GERFAUD, Loic TOMAS
  • Patent number: 10377694
    Abstract: The invention relates to new compounds of the general formula (I): as well as the use thereof in pharmaceutical compositions intended for use in human or veterinary medicine (dermatological, rheumatic, respiratory, cardiovascular and ophthalmological disorders, in particular), or in the use of cosmetic compositions.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: August 13, 2019
    Assignee: Galderma Research & Development
    Inventor: Thibaud Portal
  • Patent number: 10343999
    Abstract: The present invention relates to a novel process for preparing enantiomerically pure compounds of N-(pyrid-4-yl)-2-hydroxyalkylamide type corresponding to the general formula (C) below: and also to processes for preparing the reaction intermediates used in this synthesis, said intermediates having the general formulae (A) and (B) below:
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: July 9, 2019
    Assignee: Galderma Research & Development
    Inventors: Jean-Guy Boiteau, Sebastien Daver, Nicolas Rodeville
  • Publication number: 20190169375
    Abstract: A new hydrogel made of crosslinked glycosaminoglycans, particularly crosslinked hyaluronic acid, chondroitin or chondroitin sulfate, having reversible linkages using boronic acid or boroxole derivatives leading to new benefits. Glycosaminoglycans that are crosslinked via an alkoxyboronate ester anion formed between a diol portion of a diol-functional moiety grafted to a first glycosaminoglycan and a boronate hemiester grafted to a second glycosaminoglycan.
    Type: Application
    Filed: August 2, 2017
    Publication date: June 6, 2019
    Applicants: Galderma Research & Development, Centre National de la Recherche Scientifique
    Inventors: Rachel AUZELY-VELTY, Tamiris FIGUEIREDO, Laura JING JING, Craig Steven HARRIS, Jean-Guy BOITEAU, Thibaut GERFAUD, Loic TOMAS
  • Patent number: 10202346
    Abstract: The use of compounds in the treatment of skin disorders is described. In particular, use of a compound of formula (I): or one of its pharmaceutically acceptable salts, solvates or hydrates in the preparation of a medicament to treat skin pathologies is described.
    Type: Grant
    Filed: July 27, 2015
    Date of Patent: February 12, 2019
    Assignee: Galderma Research & Development
    Inventors: Cedric Poinsard, Pascal Collette, Pascale Mauvais, Jean-Michel Linget, Sandrine Rethore
  • Publication number: 20190010124
    Abstract: The present invention relates to a novel process for preparing enantiomerically pure compounds of N-(pyrid-4-yl)-2-hydroxyalkylamide type corresponding to the general formula (C) below: and also to processes for preparing the reaction intermediates used in this synthesis, said intermediates having the general formulae (A) and (B) below:
    Type: Application
    Filed: November 8, 2016
    Publication date: January 10, 2019
    Applicant: Galderma Research & Development
    Inventors: Jean-Guy BOITEAU, Sébastien DAVER, Nicolas RODEVILLE
  • Publication number: 20180284094
    Abstract: The invention relates to a method for determining in vitro release rate of at least one active principle ingredient from at least one semisolid form.
    Type: Application
    Filed: May 13, 2016
    Publication date: October 4, 2018
    Applicant: Galderma Research & Development
    Inventors: Brzokewicz Alain, Hélène Huguet
  • Patent number: 9814690
    Abstract: Dermatological/cosmetic compositions suited for preventing or treating cell differentiation and/or proliferation and/or keratinization disorders, including preventing or treating common acne, comprise, in a physiologically acceptable medium, (i) at least one dispersed retinoid, (ii) dispersed benzoyl peroxide, in free or encapsulated form, and (iii) at least one pH-independent gelling agent, selected from the group consisting of (a) polyacrylamide gelling agents, (b) gelling agents which are acrylic polymers coupled to hydrophobic chains, (c) modified starch gelling agents, and mixture thereof, said composition maintaining good chemical stability of (i) and (ii) without their degradation over time at a temperature of between 4° C. and 40° C.
    Type: Grant
    Filed: March 24, 2008
    Date of Patent: November 14, 2017
    Assignee: Galderma Research & Development
    Inventors: Sandrine Orsoni, Nathalie Willcox
  • Patent number: 9554988
    Abstract: Methods, compositions and products for preventing skin tumor formation or inhibiting the development of an existing skin tumor in a subject are described. The methods involve administering to the subject a composition containing an ? adrenergic receptor agonist, such as brimonidine.
    Type: Grant
    Filed: June 29, 2011
    Date of Patent: January 31, 2017
    Assignee: Galderma Research & Development
    Inventors: Guy Bouvier, Matthew James Leoni, Michael Graeber
  • Patent number: 9499310
    Abstract: A combination includes a child-resistant package and a collapsible tube removably positionable therein. A sidewall of a body of the package has an interior surface and an opposing exterior surface. A cavity is defined by the body. An opening is positioned proximate an open first end of the body. A bottom wall is positioned proximate an open second end of the body. A cap is removably mounted onto at least a portion of the first end of the body. The collapsible tube is surrounded by the body, the bottom wall and the cap when the cap is mounted onto at least a portion of the first end of the body. The collapsible tube includes a generally flexible housing defining a cavity for holding a substance to be dispensed from the housing. A closure is removably mounted onto the housing.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: November 22, 2016
    Assignee: Galderma Research & Development
    Inventor: Sebastien Fily
  • Patent number: 9327897
    Abstract: A combination includes a container having a body with a first end and a second end. The body defines a cavity for holding contents to be dispensed from the container. An actuator is positioned proximate to the first end of the body. The actuator is operatively connected to the cavity to allow the contents to be dispensed therefrom. At least two diametrically opposed first fastening members are positioned on or in the body. A device has a generally open first end, a generally open second end, and a sidewall extending therebetween. The device is removably mountable onto the body of the container. At least two diametrically opposed second fastening members are positioned on or in an interior surface of the sidewall. Each second fastening member engages at least a portion of one of the first fastening members of the container when the device is mounted onto the container.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: May 3, 2016
    Assignee: Galderma Research & Development
    Inventor: Sebastien Fily
  • Publication number: 20150376126
    Abstract: A method is described for the synthesis of 4-piperidin-4-yl-benzene-1,3-diol of the following formula (I): and the pharmaceutically acceptable salts thereof.
    Type: Application
    Filed: February 14, 2014
    Publication date: December 31, 2015
    Applicant: Galderma Research & Development
    Inventors: Jean-Guy BOITEAU, Branislav MUSICKI
  • Patent number: 9050246
    Abstract: The present invention concerns an injectable composition comprising a filler or a botulinum toxin and an adrenergic receptor agonist, and its use for diminishing, decreasing or avoiding skin reactions due to injection, specially redness, ecchymosis, bruising, bleeding, erythema, oedema, necrosis, ulceration, swelling and/or inflammation.
    Type: Grant
    Filed: May 28, 2010
    Date of Patent: June 9, 2015
    Assignee: Galderma Research & Development
    Inventors: Isabelle Bertholon, Florence Brunel, Benjamin Herbage, Sylviane Villard